Ikena Oncology (NASDAQ:IKNA - Get Free Report) announced its earnings results on Thursday. The company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.08, Zacks reports.
Ikena Oncology Trading Up 4.4%
Shares of NASDAQ:IKNA traded up $0.06 during midday trading on Friday, reaching $1.43. 445,143 shares of the company were exchanged, compared to its average volume of 411,726. The business's fifty day moving average is $1.31 and its two-hundred day moving average is $1.32. Ikena Oncology has a one year low of $0.97 and a one year high of $1.94. The stock has a market cap of $69.01 million, a PE ratio of -2.23 and a beta of 0.50.
Ikena Oncology's stock is set to reverse split on Monday, July 28th. The 1-12 reverse split was announced on Friday, July 25th. The number of shares owned by shareholders will be adjusted after the market closes on Friday, July 25th.
Analyst Ratings Changes
Separately, Wedbush reduced their price objective on shares of Ikena Oncology from $25.00 to $23.00 and set a "neutral" rating for the company in a research note on Friday.
Check Out Our Latest Research Report on IKNA
Hedge Funds Weigh In On Ikena Oncology
A hedge fund recently raised its stake in Ikena Oncology stock. Goldman Sachs Group Inc. raised its holdings in shares of Ikena Oncology, Inc. (NASDAQ:IKNA - Free Report) by 62.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 76,464 shares of the company's stock after purchasing an additional 29,369 shares during the quarter. Goldman Sachs Group Inc. owned 0.16% of Ikena Oncology worth $98,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 75.00% of the company's stock.
About Ikena Oncology
(
Get Free Report)
Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Ikena Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ikena Oncology wasn't on the list.
While Ikena Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
